CEDIA N-Acetylprocainamide Assay
by Boehringer Mannheim Corp. 510(k)
Active
510(k) K963306
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA 510(k)SESE | NumberK963306 | Date29 Oct 1996 | StatusActive |
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA 510(k) Active
Recalls
No FDA recalls on record, checked 6 Oct 2026.
Specification
- 510(k) Number
- FDA Product Code
- LAR
- Device Class
- Class II
- Regulation
- 21 CFR Part 862.3320
- Advisory Committee
- Clinical Toxicology
- FDA Decision
- SESE Substantially Equivalent
Overview
AI-generated summary, 1 Oct 2026
The CEDIA N-Acetylprocainamide Assay is an in vitro diagnostic medical device intended for the quantitation of N-Acetylprocainamide in human serum or plasma. It is classified as an Enzyme Immunoassay for Procainamide and operates under product code LAR.
This device is supplied as a Class II medical device with special controls and was cleared by the FDA on October 29, 1996 under 510(k) number K963306. It is manufactured by Boehringer Mannheim Corp. in Concord, CA, and is intended for use in clinical toxicology settings. The device is not specified as single-use or reusable, and no information regarding sterility, MRI safety, or storage conditions is provided.
Other devices from Boehringer Mannheim Corp.
Questions
AI-generated answers, 1 Oct 2026
What is the CEDIA N-Acetylprocainamide Assay used for?
This in vitro diagnostic device is designed for the quantitation of N-Acetylprocainamide in human serum or plasma, specifically intended for use in clinical toxicology settings to monitor drug levels.
How is the CEDIA N-Acetylprocainamide Assay supplied?
The device is supplied as a Class II medical device with special controls. It is manufactured by Boehringer Mannheim Corp. in Concord, CA, and is not specified as single-use or reusable in the provided information.
What is the regulatory status of the CEDIA N-Acetylprocainamide Assay?
This device was cleared by the FDA on October 29, 1996 under 510(k) number K963306, classified as substantially equivalent to predicate devices for the quantitation of N-Acetylprocainamide in human serum or plasma.
What is the product code and classification of this assay?
The CEDIA N-Acetylprocainamide Assay operates under product code LAR and is classified as an Enzyme Immunoassay for Procainamide, with FDA clearance indicating it meets safety and effectiveness requirements for its intended use.